Results of an antimicrobial stewardship program

Results of antimicrobial stewardship program in a tertiary care hospital: ambispective cohort study - PROGEAN-FARM

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

RPCEC

Registry ID

RPCEC00000275

Enrollment

514

Registered

2018-05-30

Start date

2016-08-05

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious diseases

Interventions

The study is composed of two cohorts, a prospective cohort or exposed to the protective factor (considering a protective factor as the evaluation of antimicrobial therapy by the Pharmacist in the envi

And of complete therapy: a) duplicity and b) drug interactions. The unexposed cohort is a retrospective population (July 2016 backwards) that is similar (paired) in sociodemographic, clinical and m

Antimicrobial Stewardship

Program Evaluation

Evaluation of Results of Therapeutic Interventions

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patient older than 18 years. 2. Patients who, within their pharmacotherapy, have a minimum prescribed one of the following antibiotics: • Penicillins: Piperacillin / Tazobactam. • Cephalosporins: Ceftriaxone, Ceftazidime, Cefepime, Ceftaroline. • Carbapenems: Meropenem, Doripenem, Imipenem / Cilastatin, Ertapenem. • Quinolones: Ciprofloxacin. • Glycopeptides: Vancomycin. • Polymyxins: Polymyxin B, Colistin • Oxazolidinones: Linezolid. • Cyclic lipopeptides: Daptomycin. • Tetracyclines: Tigecycline.

Exclusion criteria

Exclusion criteria: 1. Patients without the first evaluation by the treating medical specialty. 2. Patients receiving extracorporeal membrane oxygenation (ECMO). 3. Patients with cystic fibrosis. and. Administration of antimicrobials subcutaneously, intraperitoneally or intrathecally. 4. Patients admitted to surgery and hemodynamics.

Design outcomes

Primary

Measure	Time frame
Consumption of carbapenemic antimicrobials (The Defined Daily Dose will be used as a mean daily dose when a drug (antibiotic) is used in its main indication in adults. In this case, the daily dose defined by 100 patient-days will be calculated, using the formula DDD/100 patients-day = g Antimicrobial x (100 / DDD specific (g) n ° days x n ° patients)). Measurement time: at the end of antibiotic treatment.	—

Measure

Time frame

Consumption of carbapenemic antimicrobials (The Defined Daily Dose will be used as a mean daily dose when a drug (antibiotic) is used in its main indication in adults. In this case, the daily dose defined by 100 patient-days will be calculated, using the formula DDD/100 patients-day = g Antimicrobial x (100 / DDD specific (g) n ° days x n ° patients)). Measurement time: at the end of antibiotic treatment.

—

Secondary

Measure	Time frame
Duration of antibiotic treatment (It will be measure in Days). Measurement time: at the end of antibiotic treatment. Costs associated with antibiotic treatment (It will be measure in American dollars). Measurement time: at the end of antibiotic treatment.	—

Countries

Colombia

Contacts

Public ContactHector Holguin Yepes

Clínica Medellin

hector.holguin30@gmail.com

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Aug 15, 2026